dc.contributor
Institut Català de la Salut
dc.contributor
Medical Oncology Service, Breast Cancer Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Escriva de Romaní Muñoz, Santiago Ignacio
dc.contributor.author
Saura Manich, Cristina
dc.date.accessioned
2025-10-25T05:39:00Z
dc.date.available
2025-10-25T05:39:00Z
dc.date.issued
2023-05-02T10:57:10Z
dc.date.issued
2023-05-02T10:57:10Z
dc.date.issued
2023-01-12
dc.identifier
Escrivá-de-Romaní S, Saura C. The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates. Cancer Drug Resist. 2023 Jan 12;6:45–58.
dc.identifier
https://hdl.handle.net/11351/9449
dc.identifier
10.20517/cdr.2022.52
dc.identifier.uri
http://hdl.handle.net/11351/9449
dc.description.abstract
Breast cancer; HER2-positive; New drugs
dc.description.abstract
Càncer de mama; HER2-positiu; Nous medicaments
dc.description.abstract
Cáncer de mama; HER2 positivo; Nuevos fármacos
dc.description.abstract
HER2-positive breast cancer is an aggressive disease. As a result of the development of specific HER2-targeted therapies, such as trastuzumab, more than 20 years ago, the prognosis of these patients has improved. Metastatic HER2-positive breast cancer patients are achieving better survival rates upon treatment with anti-HER2 therapies than patients with HER2-negative disease. Double HER2 blockade with trastuzumab and pertuzumab combined with a taxane achieved an unprecedented survival of over 57 months in first-line patients. Trastuzumab emtansine, the first antibody-drug conjugate approved for patients in second-line treatment was a potent cytotoxic agent bound to trastuzumab and is currently a standard therapeutic strategy. Despite the progress in treatment development, most patients develop resistance and eventually relapse. Advances in the design of antibody-drug conjugates have led to the development of new generation drugs with enhanced properties, such as trastuzumab deruxtecan and trastuzumab duocarmazine, which are significantly changing the paradigm in the treatment of HER2-positive metastatic breast cancer.
dc.format
application/pdf
dc.publisher
OAE Publishing
dc.relation
Cancer Drug Resistance;6
dc.relation
http://dx.doi.org/10.20517/cdr.2022.52
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
Anticossos monoclonals - Ús terapèutic
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.title
The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
